Concepedia

Gregory D. Busse

GD

Statistics

Publications

23

Citations

586

H-Index

16

Active since

1970

Affiliations

Supernus Pharmaceuticals (United States)(Current)

American University

SUNY Upstate Medical University

Neuroscience Education Institute

Medical University of South Carolina

Gregory D. Busse is an author at Supernus Pharmaceuticals (United States) specializing in social sciences, addiction, and medicine.

Top concepts

Publications per year

1970–2024

23

Publications

23

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2020 · 81 citations · Full text

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2021 · 53 citations

, , +11

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Journal of Clinical Psychopharmacology · 2021 · 40 citations · Full text

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · PubMed · 2021 · 36 citations · Full text

The interaction of sex and route of drug administration in cocaine-induced conditioned taste aversions

Gregory D. Busse, Kevin B. Freeman, Anthony L. Riley · Pharmacology Biochemistry and Behavior · 2005 · 33 citations

, , +11

1–5 of 23